Impact of magnetic resonance imaging on cardiac mortality in thalassemia major

Journal of Magnetic Resonance Imaging

Volumn 34, Issue 1, 2011, Pages 56-59

  Chouliaras, Giorgos ^a   Berdoukas, Vasilios ^a   Ladis, Vassilis ^a   Kattamis, Antonis ^a   Chatziliami, Antonia ^b   Fragodimitri, Christina ^b   Karabatsos, Fotis ^b   Youssef, Jacqueline ^b   Karagiorga Lagana, Markissia ^b  

^a UNIVERSITY OF ATHENS   (Greece)

^b AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

Author keywords

cardiac death; iron chelation therapy; iron overload; magnetic resonance imaging (MRI); thalassemia major

Indexed keywords

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; CHELATION THERAPY; CLINICAL DECISION MAKING; CONTROLLED STUDY; FEMALE; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL; THALASSEMIA MAJOR;

ADULT; BETA-THALASSEMIA; BLOOD TRANSFUSION; CHELATING AGENTS; DEATH; HEART; HUMANS; IRON; IRON OVERLOAD; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PROPORTIONAL HAZARDS MODELS; REGRESSION ANALYSIS; RISK; TREATMENT OUTCOME;

EID: 79959618544     PISSN: 10531807     EISSN: 15222586     Source Type: Journal    
DOI: 10.1002/jmri.22621     Document Type: Article

References (22)

1. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187-1193. (Pubitemid 39390442)
2. Ladis V, Chouliaras G, Berdousi H, Kanavakis E, Kattamis C,. Longitudinal study of survival and causes of death in patients with thalassemia major in Greece. Ann N Y Acad Sci 2005; 1054: 445-450. (Pubitemid 43031054)
3. Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J 2001; 22: 2171-2179. (Pubitemid 33139463)
4. Hekmatnia A, Radmard AR, Rahmani AA, Adibi A, Khademi H,. Magnetic resonance imaging signal reduction may precede volume loss in the pituitary gland of transfusion-dependent beta-thalassemic patients. Acta Radiol 2010; 51: 71-77.
5. Noetzli LJ, Papudesi J, Coates TD, Wood JC,. Pancreatic iron loading predicts cardiac iron loading in thalassemia major. Blood 2009; 114: 4021-4026.
6. Au WY, Lam WW, Chu WW, et al. Organ-specific hemosiderosis and functional correlation in Chinese patients with thalassemia intermedia and hemoglobin H disease. Ann Hematol 2009; 88: 947-950.
7. Papakonstantinou O, Ladis V, Kostaridou S, et al. The pancreas in beta-thalassemia major: MR imaging features and correlation with iron stores and glucose disturbances. Eur Radiol 2007; 17: 1535-1543. (Pubitemid 46767602)
8. Ladis V, Chouliaras G, Berdoukas V, et al. Relation of chelation regimes to cardiac mortality and morbidity in patients with thalassaemia major: an observational study from a large Greek unit. Eur J Haematol 2010; 85: 335-344.
9. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ,. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2008; 10: 42.
10. Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733-3737.
11. Piga A, Gaglioti C, Fogliacco E, Tricta F,. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Haematologica 2003; 88: 489-496. (Pubitemid 36648438)
12. Wu KH, Chang JS, Tsai CH, Peng CT,. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. Ann Hematol 2004; 83: 471-473. (Pubitemid 38877974)
13. Farmaki K, Tzoumari I, Pappa C, Chouliaras G, Berdoukas V,. Normalisation of total body iron load with very intensive combined chelation reverses cardiac and endocrine complications of thalassaemia major. Br J Haematol 2010; 148: 466-475.
14. Tsironi M, Deftereos S, Andriopoulos P, Farmakis D, Meletis J, Aessopos A,. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report. Eur J Haematol 2005; 74: 84-85. (Pubitemid 40143694)
15. Tavecchia L, Masera N, Russo P, et al. Successful recovery of acute hemosiderotic heart failure in beta-thalassemia major treated with a combined regimen of desferrioxamine and deferiprone. Haematologica 2006; 91 (6 Suppl): ECR19.
16. Kirk P, Roughton M, Porter JB, et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Circulation 2009; 120: 1961-1968.
17. Tanner MA, Galanello R, Dessi C, et al. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. J Cardiovasc Magn Reson 2006; 8: 543-547.
18. Aessopos A, Fragodimitri C, Karabatsos F, et al. Cardiac magnetic resonance imaging R2* assessments and analysis of historical parameters in patients with transfusion-dependent thalassemia. Haematologica 2007; 92: 131-132. (Pubitemid 46232670)
19. Berdoukas V, Chouliaras G, Moraitis P, Zannikos K, Berdoussi E, Ladis V,. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. J Cardiovasc Magn Reson 2009; 11: 20.
20. Tanner MA, Galanello R, Dessi C, et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Circulation 2007; 115: 1876-1884. (Pubitemid 46598901)
21. Chouliaras G, Yiannoutsos CT, Berdoukas V, Ladis V,. Cardiac related death in thalassaemia major: time trend and risk factors in a large Greek unit. Eur J Haematol 2009; 82: 381-387.
22. Forni GL, Puntoni M, Boeri E, Terenzani L, Balocco M,. The influence of treatment in specialized centers on survival of patients with thalassemia major. Am J Hematol 2009; 84: 317-318.